{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"84"}]}],"title":"Any adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"66"}]}],"title":"Adverse event ≥ grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"57"}]}],"title":"Serious adverse events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"title":"Fatal adverse events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"20"}]}],"title":"AE leading to discontinuation of carfilzomib"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"description":"Adverse events (AEs) were assigned a severity grade using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading scale version 3.0.\n\nPer protocol, adverse events were collected if they led to dose modification or dose discontinuation, were grade ≥ 3 or serious, or were events of peripheral neuropathy (any grade).\n\nA serious AE is one that met one or more of the following criteria:\n\n* Death\n* Life threatening\n* Required inpatient hospitalization or prolongation of an existing hospitalization\n* Resulted in persistent or significant disability/incapacity\n* A congenital anomaly/birth defect in the offspring of an exposed subject\n* Important medical events that, based upon appropriate medical judgment, jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes above.","groups":[{"description":"Participants with solid tumors received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.","id":"OG000","title":"Solid Tumors"},{"description":"Participants with multiple myeloma received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.","id":"OG001","title":"Multiple Myeloma"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 dose of carfilzomib after enrollment in PX-171-010.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"participants"}